We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mitomycin-c Application for PRK

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01504282
First Posted: January 5, 2012
Last Update Posted: January 5, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Shahid Beheshti University of Medical Sciences
January 4, 2012
January 5, 2012
January 5, 2012
Not Provided
Not Provided
Central corneal endothelial cell density (ECD) 6 months after the PRK [ Time Frame: 6 months ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Mitomycin-c Application for PRK
Mitomycin-c Application for Photorefractive Keratectomy
To evaluate the safety and efficacy of 5 seconds mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for patients with low myopia.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Myopia
  • Drug: mitomycin-C
  • Drug: Placebo
    balanced salt solution (BSS)
  • Active Comparator: MMC group
    One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
    Intervention: Drug: mitomycin-C
  • Placebo Comparator: BSS group
    One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
Not Provided
Not Provided

Inclusion Criteria:

  • The inclusion criteria was ablation depth less than 65 µm,
  • a stable refractive error for at least 1 year
  • corrected distance visual acuity (CDVA) of 0.1 LogMAR or better.

Exclusion Criteria:

  • Patients with keratoconus suspect,
  • excessive dry eyes,
  • impaired wound healing processes,
  • lenticular changes,
  • corneal dystrophy,
  • history of ocular surgery,
  • anterior or posterior uveitis,
  • glaucoma and retinal diseases were excluded.
Sexes Eligible for Study: All
Child, Adult, Senior
Not Provided
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
 
NCT01504282
8901
Not Provided
Not Provided
Not Provided
Not Provided
Shahid Beheshti University of Medical Sciences
Not Provided
Not Provided
Shahid Beheshti University of Medical Sciences
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP